News J&J cuts $3.3bn deal to buy eye drug developer Ollin Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2bn upfront, adding a keenly anticipated therapy for ophthalmic disorders.
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
News FDA clears Roche's Enspryng for thyroid eye disease Roche has claimed US approval for Enspryng in a second indication, thyroid eye disease, that makes it a rival to drugs from Amgen and Viridian.
News MSD data reveal undercuts eye drug remigromig's potential In its decanting of the BRUNELLO trial of remigromig for diabetic macular oedema, MSD seems to have left observers contemplating a glass half empty.
News Wnt drug gives MSD first eye disease win after EyeBio deal MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
News Beacon's XLRP gene therapy set for filing after phase 3 win Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.